This article is more than 5 years old. Information may no longer be current.
FDA grants orphan drug designation to protein kinase CK2 inhibitor for cholangiocarcinoma
Click Here to Manage Email Alerts
The FDA has issued orphan drug designation to CX-4945 for the treatment of cholangiocarcinoma, which will expedite its development, the manufacturer announced.
CX-4945 (Senhwa Biosciences) is a novel, small molecule, protein kinase CK2 inhibitor that “plays an important role in the DNA damage repair mechanisms of cancer cells,” according to a press release. Studies have shown the drug has favorable safety, pharmacokinetic and pharmacodynamic profiles in the treatment of advanced cholangiocarcinoma, for which early detection is difficult. The 5-year survival rate is about 20% and there are limited treatment options.
“The Orphan Drug Designation represents an important milestone in the development and regulatory strategy for Senhwa’s CX-4945 in providing a new treatment option for cholangiocarcinoma,” Tai-Sen Soong, PhD, CEO of Senhwa Biosciences, said in the press release. “We look forward to seeing the results from our ongoing phase II clinical trial.”
Disclosures: Soong is employed by Senhwa Biosciences.